Corcept Therapeutics Faces Class Action Lawsuit Over Misleading Drug Approval Claims

Corcept Therapeutics Under Legal Scrutiny: Class Action Filed

In recent developments, Corcept Therapeutics Inc. (CORT) is currently embroiled in a securities class action lawsuit, a situation that has raised alarms for investors. The firm Hagens Berman, known for defending shareholder rights, has issued a notice indicating that they are now representing investors in this case. The lawsuit, officially titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated (No. 26-cv-01525), primarily aims to address grievances related to stock purchases made between October 31, 2024, and December 30, 2025.

Allegations of Misrepresentation

The nature of the allegations against Corcept centers on claims that the company misled investors about the regulatory approval process for their flagship product, relacorilant. According to the lawsuit, while Corcept maintained a narrative of confidence regarding the drug's impending approval, significant behind-the-scenes warnings from the FDA indicated otherwise. The lawsuit contends that executives of Corcept were aware of the FDA's concerns regarding the clinical data supporting relacorilant but chose to disregard these issues in their communications with shareholders.

The complaint details allegations that during pre-submission meetings with the FDA, officials had warned Corcept about the inadequacy of their clinical development program relating to relacorilant's effect on hypertension. Such information was allegedly withheld from investors, potentially manipulating the market's perception of the company's prospects.

The Day of Reckoning: December 31, 2025

A pivotal moment in the case unfolded on December 31, 2025, when Corcept revealed it had received a Complete Response Letter (CRL) from the FDA regarding relacorilant. This announcement had catastrophic implications for the company’s stock, as shares plummeted from $70.20 to $34.80 within a single day, resulting in a loss of over $3.6 billion in market capitalization.

The CRL indicated that the FDA was not able to arrive at a favorable benefit-risk assessment for the drug without additional effectiveness data, confirming the worries that had been communicated previously by the FDA. Following this, the company faced further scrutiny as redacted versions of the CRL disclosed more insights, underscoring the struggles Corcept was facing.

Important Deadlines and Next Steps

For investors affected by this situation, Hagens Berman has set an important deadline of April 21, 2026, urging those who bought Corcept stock during the class period to step forward. Investors with substantial losses are highlighted as particularly crucial to building the case, and they are encouraged to reach out to the firm to discuss possible participation as lead plaintiffs.

Reed Kathrein, a leading attorney at Hagens Berman, expressed the gravity of the allegations, emphasizing the stark difference between the optimistic public statements made by Corcept and the warnings received from the FDA. He noted, "The litigation targets the alleged gap between Corcept's 'high confidence' narrative and the private warnings from the FDA."

Call to Action for Potential Whistleblowers

Additionally, Hagens Berman is offering incentives for whistleblowers with non-public information regarding Corcept to assist in the investigation. Under the new SEC Whistleblower program, individuals may be entitled to rewards up to 30% of any recoveries this case yields.

For those who wish to gather more information about the case or participate in the initiative, contacting the Hagens Berman firm is encouraged. The transparency in their approach represents a crucial step in seeking accountability in corporate practices regarding investor communications.

Conclusion

With the upcoming deadline of April 21 approaching, it is essential for investors to act quickly if they wish to assert their rights in this ongoing litigation against Corcept Therapeutics. The implications of this case extend beyond financial loss, raising questions about corporate ethics and the responsibilities of pharmaceutical companies in relaying accurate information to stakeholders.